２回接種、９割に変異株抗体　ファイザー製ワクチン―横浜市立大

　横浜市立大の山中竹春教授らの研究チームは１２日、米製薬大手ファイザーの新型コロナウイルスワクチンの接種を２回受けた人の約９割に、英国型などの変異株への感染を防ぐ中和抗体があったと発表した。１回の接種では不十分だったという。山中教授は「集団免疫に期待が持てる結果が出た。現在の変異なら、既存ワクチンで対応できるのでは」と話した。
　研究チームは、ファイザー製ワクチンの接種を受け、新型コロナの感染歴がない同大付属病院の職員ら１０５人を調査。英国型や南アフリカ型など７種類の変異株と従来株の計８種類に対する抗体保有率を調べた。
　英国型への抗体保有率は、１回目の接種後は１８％だったが、２回目の後は９４％に増加。同様に南ア型は２１％が９０％に、ブラジル型は１６％が９４％にそれぞれ上昇した。インド型も３７％が９７％に上がった。（2021/05/12-16:53）

Some 90 pct of people who have received two jabs of the novel coronavirus vaccine from Pfizer Inc. developed neutralizing antibodies against variant strains, a Japanese research team said Wednesday.
   The proportion of those who acquired such antibodies after being administered their first shots was relatively low, according to the team, led by Takeharu Yamanaka, professor at Yokohama City University.
   "The finding gives hope for herd immunity," Yamanaka said. "We may be able to deal with the existing variants with the vaccines we have now."
   The survey covered 105 staff members of the university's hospital with no record of coronavirus infection who were given the Pfizer vaccine, and the team studied the proportion of people who developed neutralizing antibodies against seven mutant strains, including those originating from British and South Africa, and the conventional strain.
   Whereas only 18 pct of those after their first jabs had antibodies that can fend off infections with the British variant, 94 pct had the antibodies after their second jabs.